Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused byPseudomonas aeruginosa | Zendy

Norihito Kaku | Zendy; Yoshitomo Morinaga | Zendy; Kazuaki Takeda | Zendy; Kosuke Kosai | Zendy; Naoki Uno | Zendy; Hiroo Hasegawa | Zendy; Taiga Miyazaki | Zendy; Koichi Izumikawa | Zendy; Hiroshi Mukae | Zendy; Katsunori Yanagihara | Zendy

Open Access

Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused byPseudomonas aeruginosa

Author(s) -

Norihito Kaku,

Yoshitomo Morinaga,

Kazuaki Takeda,

Kosuke Kosai,

Naoki Uno,

Hiroo Hasegawa,

Taiga Miyazaki,

Koichi Izumikawa,

Hiroshi Mukae,

Katsunori Yanagihara

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw517

Subject(s) - amikacin , pharmacokinetics , medicine , pharmacology , pneumonia , aminoglycoside , pseudomonas aeruginosa , antibiotics , anesthesia , microbiology and biotechnology , bacteria , biology , genetics

Arbekacin is an aminoglycoside that shows strong antimicrobial activity against Gram-positive bacteria, including MRSA, as well as Pseudomonas aeruginosa . The therapeutic effectiveness of arbekacin is directly related to C max at the infection site. To maximize drug delivery to the respiratory tract and minimize the systemic toxicity, arbekacin optimized for inhalation, ME1100, is under development. In this study, we investigated the efficacy and pharmacokinetics of ME1100 in a murine model of ventilator-associated pneumonia caused by P. aeruginosa by using a customized investigational nebulizer system.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research